Looking ahead to 2026, Doustdar said Novo Nordisk had high expectations for the potential launches of new incretin ...

The loss of market exclusivity for a trio of big-selling drugs in the last quarter of 2025 dragged down Novartis sales, but ...

"The government has claimed that the deal will only cost around £1 billion per year, but the UK's new commitment to double ...

There’s no doubt that large language models and generative AI tools have taken the world by storm. Their ability to create, ...

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Lisa Sims, executive director of learning strategy & ...

Wave Life Sciences has lost GSK as the partner for its RNA-editing drug for alpha-1 antitrypsin deficiency (AATD), just over ...

ICH E6 (R3) introduces a dedicated section on data governance, reflecting the increasing complexity of data sources and ...

AstraZeneca's new formulation of systemic lupus erythematosus (SLE) therapy Saphnelo has been turned down by the FDA, despite getting the go-ahead in Europe a few weeks ago.

The UK government has set aside a £10 million (nearly $14 million) financial support package to help support families with ...

As this complexity deepens, a simple truth emerges: classical measurement frameworks cannot keep pace with a system that is ...

Joenja is a sizeable contributor to Pharming's revenues, accounting for €38 million ($45 million) of its total sales of €70 ...

Novo Nordisk is considering additional regulatory filings for CagriSema – already submitted in the US for obesity – after the drug outperformed Ozempic in a head-to-head diabetes study.